Showing 1011-1020 of 1583 results for "".
- Closing the Healthcare Gender Gap as a Key to Optimize Female Longevityhttps://modernaesthetics.com/news/closing-the-healthcare-gender-gap-as-a-key-to-optimize-female-longevity/2473748/"The story of women's struggle for equality belongs to no single feminist nor to any one organization but to the collective efforts of all who care about human rights." —Gloria Steinem The United Nations has declared the theme for this year’s International
- Skinbetter Science Launches BioRewind Skin Health Dietary Supplement to Combat Skin Glycationhttps://modernaesthetics.com/news/skinbetter-science-launches-biorewind-skin-health-dietary-supplement-to-combat-skin-glycation/2473747/Skinbetter science launched BioRewind, a skin health dietary supplement with a purpose of visibly improving skin quality by helping reduce advanced glycation endproducts (AGEs), on Monday. Glycation is a key contributor to skin aging and this supplement’s formula is clinically demonstrate
- 2025 Octane Aesthetics Tech Forum: The Growth of Hair Panelhttps://modernaesthetics.com/news/the-growth-of-hair-2025-octane-aesthetics-tech-forum/2473741/The Growth of Hair panel at the 2025 Octane Aesthetics Tech Forum brought together leading experts in dermatology, pharmacology, and regenerative medicine to discuss exciting advancements in hair loss treatments and technologies. The panel included Ken Washenik, MD; Wajdie Ahmad, Co-Founder &
- FDA Approves New HA Gels From Evolushttps://modernaesthetics.com/news/fda-approves-new-ha-gels-from-evolus/2473740/The US Food and Drug Administration has approved Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection, Evolus announced. These approvals mark Evolus’ entry into the United States HA dermal filler market and solidifies the com
- Merz Aesthetics Releases Findings of Inaugural Global Study Connecting Aesthetics and Self-Affirmationhttps://modernaesthetics.com/news/merz-aesthetics-releases-findings-of-inaugural-global-study-connecting-aesthetics-and-self-affirmation/2473732/Merz Aesthetics launched its inaugural global study in Paris on Wednesday ahead of IMCAS World Congress. The Pillars of Confidence: Global Insights on Aesthetics and Self-Affirmation study, with research support from Ipsos, explores the role confidence plays in daily life and overall well-being,
- Galderma Seeks to Address Facial Volume Loss From GLP-1 Medications with Injectable Portfoliohttps://modernaesthetics.com/news/new-datas-promising-results-to-predominant-aesthetic-concerns-for-prescription-weight-loss-medications/2473730/Galderma announced positive first results last week from a trial designed to explore the benefits of Restylane Lyft or Contour in combination with Sculptra in patients with medication-driven weight loss with associated facial volume loss. According to a press release from the manufacturer,
- New Data Reveals GLP-1 Medications Impact on Medical Aesthetics Growthhttps://modernaesthetics.com/news/new-data-reveals-glp-1-medications-impact-on-medical-aesthetics-growth/2473724/Guidepoint Qsight revealed new insights Thursday on the state of the $17.5 billion medical aesthetics industry, which was up 2% in 2024. The findings highlight how the integration of glucagon-like peptide-1 (GLP-1) medications for weight loss is reshaping the aesthetics market. GLP-1 medic
- Report: Regenerative Aesthetics Exosome Market Poised for Growth Through 2031https://modernaesthetics.com/news/report-regenerative-aesthetics-exosome-market-poised-for-growth-through-2031/2473722/The global regenerative aesthetics exosome products market is projected to experience a compound annual growth rate (CAGR) of 35.5% from 2024 to 2031, according to a report from InsightAce Analytic. Exosome-based therapies with applications in skin reju
- Study Backs CP-GEP Tests’ Accuracyhttps://modernaesthetics.com/news/study-backs-cp-gep-tests-accuracy/2473699/Patients with clinically node-negative primary cutaneous melanoma undergoing sentinel lymph node biopsies (SLNBs) who were classified as “high risk” according to CP-GEP tests were approximately three times more likely to be SLN positive, according to data presented October 13 at the S
- New Data Demonstrates Long-Term Safety, Efficacy of Galderma’s RelabotulinumtoxinAhttps://modernaesthetics.com/news/new-data-demonstrates-long-term-safety-efficacy-of-galdermas-relabotulinumtoxina/2473698/Galderma presented new phase III data from the READY-4 clinical trial at the American Society for Dermatologic Surgery (ASDS) 2024 Annual Meeting last week. The data demonstrates the long-term safety of RelabotulinumtoxinA (RelfydessTM) for frown lines and crow’s feet after repea